Uncertainty reigns, but opportunity persists for biotech’s 2025

What It Covers

RBC Capital Markets' Brian Abrams outlines the 2025 biotech landscape, where unconventional FDA and HHS leadership nominees, $350B in pharma patent cliffs, and AI-driven drug development create simultaneous headwinds and deal-making opportunities.

Key Questions Answered

• •M&A Opportunity: Large biopharma faces over $350B in patent-cliff-exposed sales this decade and holds $150B+ in cash reserves. A more permissive FTC signals accelerating deal flow — 2025 opened with a $15B acquisition, nearly triple the largest deal of 2024.
• •Regulatory Risk Calibration: Incoming FDA Commissioner Marty Makary's historically anti-industry stance threatens to reduce new drug approval flexibility after a record 2024 for accelerated approvals. Investors should factor regulatory friction into timelines for pipeline-stage assets, particularly those relying on priority review pathways.
• •Sector Positioning: Three categories offer the strongest risk-adjusted returns: commercial-stage companies that experienced exaggerated sell-offs, companies positioned as M&A targets, and names with underappreciated near-term catalysts backed by sound mechanistic data and prior clinical evidence.
• •Macro Overhang on Small Caps: Persistently high interest rates disproportionately pressure pre-commercial biotech given five-to-ten-year drug development cycles. The Inflation Reduction Act continues adding pricing uncertainty, and $6B in Chinese pharma asset licensing by US pharma in 2024 may compress valuations of domestic small and mid-cap innovators.